{
    "root": "34a4933a-9b54-1f14-e063-6394a90a7b59",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ESZOPICLONE",
    "value": "20250508",
    "ingredients": [
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "ESZOPICLONE",
            "code": "UZX80K71OE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53760"
        }
    ],
    "indications": {
        "text": "eszopiclone tablets indicated treatment insomnia . controlled outpatient sleep laboratory , eszopiclone tablets administered bedtime decreased sleep latency improved sleep maintenance . trials performed support efficacy 6 months duration . final formal assessments sleep latency maintenance performed 4 weeks 6-week study ( adults ) , end 2-week ( elderly ) end 6-month study ( adults ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "lowest effective dose patient .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "eszopiclone tablets usp 2 mg white off-white , film-coated , round shaped , biconvex tablets debossed \u2018 k \u2019 one side \u2018 84 \u2019 side . ndc : 70518-1310-00 packaging : 30 1 bottle plastic store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "eszopiclone tablets contraindicated patients experienced complex sleep behaviors taking eszopiclone tablets [ ( 5.1 ) ] . eszopiclone tablets contraindicated patients known hypersensitivity eszopiclone . hypersensitivity include anaphylaxis angioedema [ ( 5.3 ) ] .",
    "indications_original": "Eszopiclone tablets are indicated for the treatment of insomnia. In controlled outpatient and sleep laboratory studies, eszopiclone tablets administered at bedtime decreased sleep latency and improved sleep maintenance. \n                  \n                  The clinical trials performed in support of efficacy were up to 6 months in duration.\u00a0 The final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6-month study (adults only).",
    "contraindications_original": "Use the lowest effective dose for the patient.",
    "warningsAndPrecautions_original": "Eszopiclone Tablets USP 2 mg are white to off-white, film-coated, round shaped, biconvex tablets with debossed \u2018K\u2019 on one side and \u201884\u2019 on other side.\n                  NDC: 70518-1310-00\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC\n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Eszopiclone tablets are contraindicated in patients who have experienced complex sleep behaviors after taking Eszopiclone tablets \n        \n  \n   [see \n         \n   \n    Warnings and Precautions (5.1)]. \n        \n  \n   \n                     \n                  \n                  \n                     Eszopiclone tablets are contraindicated in patients with known hypersensitivity to eszopiclone. Hypersensitivity reactions include anaphylaxis and angioedema \n        \n  \n   [see \n         \n   \n    Warnings and Precautions (5.3)]\n        \n  \n   .",
    "drug": [
        {
            "name": "ESZOPICLONE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53760"
        }
    ]
}